Warner Chilcott is to acquire Procter & Gamble’s prescription drug business in a deal worth US$3.1 billion, it was announced in August 2009.
Warner Chilcott is a specialist in women’s health, and the deal will expand its focus to musculoskeletal disorders and gastrointestinal problems too.
Procter & Gamble’s portfolio of branded drugs includes Asacol (mesalamine) for ulcerative colitis, and Actonel (risedronate), an osteoporosis drug. Warner Chilcott will also acquire Procter & Gamble’s drug pipeline.
Warner Chilcott will take over manufacturing sites in Puerto Rico and Germany, which will add to its existing sites also in Puerto Rico and in Northern Ireland. It is expected that the 2,300 Procter & Gamble employees will be transferred to the new owner.
The transaction should be completed by the end of 2009.
Further reading - In-depth reviews of the pharmaceutical markets in the USA and the UK are available from Espicom: The Pharmaceutical Market: USA (published June 2009) and The Pharmaceutical Market: United Kingdom (published June 2009)